Adeza to Present at the William Blair & Company 26th Annual Growth Stock Conference; Webcast Scheduled Wednesday, June 28 at 2:
26 6월 2006 - 5:00PM
Business Wire
Adeza (NASDAQ:ADZA) today announced that Emory V. Anderson,
president and chief executive officer, will make an investment
community presentation at the William Blair & Company 26th
Annual Growth Stock Conference on Wednesday, June 28 at 2:40 p.m.
Eastern time (1:40 p.m. Central time; 11:40 a.m. Pacific time). The
conference is being held at the Four Seasons Hotel in Chicago. A
live audio and slide webcast of the presentation will be available
via the Internet by visiting the company's Web site at
www.adeza.com. An archived presentation will be available on the
Web site for 14 days. Adeza designs, manufactures and markets
innovative products for women's health. Adeza's initial focus is on
reproductive healthcare using its proprietary technologies to
predict preterm birth and assess infertility. Adeza's principal
product is a patented diagnostic test, FullTerm(TM), The Fetal
Fibronectin Test, which utilizes a single-use, disposable cassette
and is analyzed on Adeza's patented TLiIQ(R) System. This product
is approved by the U.S. Food and Drug Administration (FDA) for use
in assessing the risk of preterm birth. Adeza also markets and
sells the E-tegrity(R) Test, an infertility-related test to assess
receptivity of the uterus to embryo implantation in women with
unexplained infertility. In May 2006, Adeza announced the
submission of a New Drug Application (NDA) with the FDA for
Gestiva, a long-acting form of a naturally occurring progesterone
to prevent preterm birth in women with a history of preterm
delivery. Adeza's NDA submission includes data from a clinical
study conducted by the National Institutes of Health. In June 2006,
the NDA for Gestiva was granted Priority Review status. More
information is available at www.adeza.com. Adeza cautions you that
statements included in this press release that are not a
description of historical facts may be forward-looking statements.
The inclusion of forward-looking statements should not be regarded
as a representation by Adeza that any of its plans will be
achieved. Actual results may differ materially from those set forth
in this release due to the risks and uncertainties inherent in
Adeza's business including, without limitation, statements about
the expansion of the indications for its products. Further
information about these and other risks is included Adeza's Annual
Report on Form 10-K and other periodic and current reports filed by
Adeza with the Securities Exchange Commission, which are available
from the SEC's Web site (www.sec.gov), and also available on the
Investor Relations section of Adeza's Web site. All forward-looking
statements are qualified in their entirety by this cautionary
statement and Adeza undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date
hereof.
Adeza (NASDAQ:ADZA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Adeza (NASDAQ:ADZA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Adeza Biomedical (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Adeza News Articles